about
Dogs Evaluate Threatening Facial Expressions by Their Biological Validity--Evidence from Gazing PatternsComparison of dogs and humans in visual scanning of social interactionEnantiospecific ketoprofen concentrations in plasma after oral and intramuscular administration in growing pigsKidney-derived proteins in urine as biomarkers of induced acute kidney injury in sheep.Sublingual administration of detomidine to calves prior to disbudding: a comparison with the intravenous route.Reactivity of dogs' brain oscillations to visual stimuli measured with non-invasive electroencephalography.Activation of complement system in kidney after ketoprofen-induced kidney injury in sheep.Human Empathy, Personality and Experience Affect the Emotion Ratings of Dog and Human Facial ExpressionsWireless and inductively powered implant for measuring electrocardiogram.How dogs scan familiar and inverted faces: an eye movement study.Adverse reactions of α2-adrenoceptor agonists in cats reported in 2003-2013 in Finland.A novel set of behavioural indicators for measuring perception of food by cats.Pain alleviation in animals: attitudes and practices of Finnish veterinarians.Thermographic imaging of superficial temperature in dogs sedated with medetomidine and butorphanol with and without MK-467 (L-659'066).Effects of MK-467 on the antinociceptive and sedative actions and pharmacokinetics of medetomidine in dogs.Visual event-related potentials of dogs: a non-invasive electroencephalography study.Effects of constant rate infusions of dexmedetomidine or MK-467 on the minimum alveolar concentration of sevoflurane in dogs.Effect of MK-467 on organ blood flow parameters detected by contrast-enhanced ultrasound in dogs treated with dexmedetomidine.24-hour Holter-monitoring in the perianaesthetic period in dogs premedicated with dexmedetomidine.A comparison of thermographic imaging, physical examination and modified questionnaire as an instrument to assess painful conditions in cats.Nasal Oxytocin Treatment Biases Dogs' Visual Attention and Emotional Response toward Positive Human Facial Expressions.Condition-based use of antimicrobials in cats in Finland: results from two surveys.Plasma drug concentrations and clinical effects of a peripheral alpha-2-adrenoceptor antagonist, MK-467, in horses sedated with detomidine.The diet board: welfare impacts of a novel method of dietary restriction in laboratory rats.Difficulties in administration of oral medication formulations to pet cats: an e-survey of cat owners.The effects of L-659,066, a peripheral alpha2-adrenoceptor antagonist, on dexmedetomidine-induced sedation and bradycardia in dogs.Cardiovascular effects of premedication with medetomidine alone and in combination with MK-467 or glycopyrrolate in dogs subsequently anesthetized with isoflurane.Effects of the α2-adrenoceptor agonist medetomidine on the distribution and clearance of alfaxalone during coadministration by constant rate infusion in dogs.Plasma concentration and cardiovascular effects of intramuscular medetomidine combined with three doses of the peripheral alpha2-antagonist MK-467 in dogs.Clinical effects and pharmacokinetic variables of romifidine and the peripheral α2 -adrenoceptor antagonist MK-467 in horses.Detomidine and the combination of detomidine and MK-467, a peripheral alpha-2 adrenoceptor antagonist, as premedication in horses anaesthetized with isoflurane.Perceptions and practices of Finnish dairy producers on disbudding pain in calves.Haemodynamic interactions of medetomidine and the peripheral alpha-2 antagonist MK-467 during step infusions in isoflurane-anaesthetised dogs.A comparison in dogs of medetomidine, with or without MK-467, and the combination acepromazine-butorphanol as premedication prior to anaesthesia induced by propofol and maintained with isoflurane.Plasma glucose, insulin, free fatty acids, lactate and cortisol concentrations in dexmedetomidine-sedated dogs with or without MK-467: a peripheral α-2 adrenoceptor antagonist.The impact of MK-467 on plasma drug concentrations, sedation and cardiopulmonary changes in sheep treated with intramuscular medetomidine and atipamezole for reversal.Influence of MK-467, a peripherally acting α2-adrenoceptor antagonist on the disposition of intravenous dexmedetomidine in dogs.The impact of medetomidine on the protein-binding characteristics of MK-467 in canine plasma.Effect of anaesthesia on contrast-enhanced ultrasound of the feline spleen.Effect of dexmedetomidine and xylazine followed by MK-467 on gastrointestinal microperfusion in anaesthetized horses.
P50
Q27342610-64D20012-1C99-4DE4-81E6-AE744DD64385Q28606815-4606A485-2765-434D-A6F6-0C8EE672BC6EQ28710485-D8543EEC-1DF3-4426-8B62-95ED364178FEQ34076044-11F4C700-3694-4480-92D2-A8719717DDC1Q34643745-C153DE36-28FB-4B72-895B-7D45B1184B31Q34708319-05014CF6-C237-4D02-920C-AD1CE8CA166EQ35186726-D67FEBD7-E2BD-4A12-91C1-F471DFE96021Q36257488-39C687A2-40AE-4E4B-A6FE-5C090853D7D6Q36967820-8C653F24-F6D3-484D-989E-0DE77CE69E8FQ38440069-8C2D8B70-5605-4874-868E-A394B3BCA4CFQ38667465-9A35BF17-0E11-4367-AA90-AAE20DE8D1ADQ39336433-00228A4B-B9BA-4559-9CCB-C9CF97D1C2F1Q39398102-3797AA87-DFDD-497D-A532-6CE0C2B8477FQ40056457-6A90B009-1E0B-4198-93C6-CEBACFCD726CQ40111915-62881F6F-5209-46F2-9952-60974E41EF7CQ43552274-7CBD1D61-F5F5-466F-BA1F-2E23B7567F74Q43721685-5F651646-4E04-4760-89B7-0D059209543CQ44214641-45753275-6D93-4CB7-854A-E6DB3D5CF4CFQ44264880-0A09284A-1E0E-43E0-A25A-5CB4F9FAD9C7Q44586554-25D9F383-5F39-4C16-B8AF-FF62E532C673Q44907043-7E94168C-185E-446A-822A-640FA4E528BBQ45391840-8F5C85E1-1585-4B91-B9CB-5AC6CC2F6877Q46006880-1B5BC7D2-6208-45CB-B514-5CB81CE9D513Q46112127-68CEB2C5-1A5A-42BC-9439-17D131C9228CQ46445456-625E8AB6-3259-427D-B75B-B802EDC1027AQ46605288-6EB51253-53DE-4084-9F8A-63A10A2343B3Q47237560-D9C4F344-98D1-4908-B0EB-D8495EF4947EQ47270904-ED4C4822-B591-4B01-8404-52C3B045EA74Q47291548-872039EF-1D18-4EA8-A8A1-484FD0BB8F8BQ47585651-BF489FDB-B858-4B9D-9C61-2180A6FA358CQ47771869-3B3FA3FE-40C3-4BD6-A39A-82D473FB7254Q47785034-24D545C8-F21A-4C29-857C-BD05DF8BF593Q47817547-C11C2AF1-0BCC-41B4-8783-259AB95B0167Q47961005-E6AA4E54-5260-4D80-9107-44C8CCE7C458Q48192084-A57F24C8-0AD7-4919-8E4D-0C68E5683EDBQ48202945-5234FF23-8F1B-4746-A5F6-2372D2C4F558Q48210960-F3FFFBDA-BDF2-4AB5-AE84-CA759A0719D9Q48263146-6027FE72-A9CA-4DE7-9654-93FBC80E2E71Q48310662-D2BFC105-9E61-46CE-9AF6-2B1D634B84C5Q50030001-6E07BC9E-EAF8-401B-971A-DE322BF24AC1
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Outi M Vainio
@ast
Outi M Vainio
@en
Outi M Vainio
@es
Outi M Vainio
@nl
Outi M Vainio
@sl
type
label
Outi M Vainio
@ast
Outi M Vainio
@en
Outi M Vainio
@es
Outi M Vainio
@nl
Outi M Vainio
@sl
prefLabel
Outi M Vainio
@ast
Outi M Vainio
@en
Outi M Vainio
@es
Outi M Vainio
@nl
Outi M Vainio
@sl
P106
P21
P31
P496
0000-0003-3467-2246
P569
2000-01-01T00:00:00Z